Human Multiple Sclerosis Single-Nucleus & Spatial Transcriptomic Atlas: MIMS Microglia, Reactive Astrocytes & OPC Remyelination Arrest

This resource from Allen Brain Map / BICCN ("Human Multiple Sclerosis Single-Nucleus & Spatial Transcriptomic Atlas: MIMS Microglia, Reactive Astrocytes & OPC Remyelination Arrest") addresses critical scientific questions within Multiple Sclerosis (MS). Research in this domain currently faces major translational bottlenecks, including progression independent of relapse activity (PIRA), smoldering neuroinflammation, and remyelination failure across white and cortical gray matter. By focusing on key thematic elements (Multiple Sclerosis, scRNA-seq, MERFISH, AnnData, PRL), this work contributes empirical evidence toward understanding how molecular, cellular, or systems-level alterations relate to core disease pathways such as paramagnetic rim lesions (PRLs), T2/FLAIR lesion volume, oligoclonal bands, EBV titers, and EDSS progression metrics. Integrating these findings into the broader open science ecosystem helps reduce fragmentation across independent laboratories and accelerates hypothesis verification.

Structured as an open scientific dataset, this repository leverages 10x snRNA-seq, MERFISH, Spatial RNA-seq across CNS Experimental / Clinical Model (185,000 Nuclei (68 Post-Mortem Lesions)). Its primary architectural value lies in providing standardized, machine-readable primary records via Allen Brain Map / BICCN under CC-BY 4.0. Unlike isolated summary tables in static publications, access to underlying 10x snRNA-seq, MERFISH, Spatial RNA-seq distributions enables independent inspection of signal-to-noise ratios, preprocessing parameter sensitivity, and cross-modality feature extraction.

Researchers and computational neuroscientists can reuse this resource across multiple secondary workflows: (1) Cross-Cohort Harmonization & Meta-Analysis — combining these 10x snRNA-seq, MERFISH, Spatial RNA-seq records with complementary repositories (such as OpenNeuro, DANDI, Agora, or Europe PMC) to increase statistical power; (2) Computational Benchmarking & Machine Learning — utilizing the documented features (Multiple Sclerosis, scRNA-seq, MERFISH, AnnData, PRL) as training, validation, or out-of-distribution test sets for predictive biomarker discovery in Multiple Sclerosis (MS); and (3) Experimental Protocol Alignment — referencing the study design (CNS Experimental / Clinical Model, 185,000 Nuclei (68 Post-Mortem Lesions)) to calibrate sample size calculations (power analysis) and endpoint selection for upcoming preclinical or clinical studies.

While curated from an authoritative scientific source, secondary analysts should account for potential cohort selection biases and site-specific batch effects. Specifically, when interpreting 10x snRNA-seq, MERFISH, Spatial RNA-seq results in Multiple Sclerosis (MS), researchers must control for confounding variables (such as age, sex, post-mortem interval, scanner/instrument drift, or medication state) and verify compliance with open-access attribution requirements (CC-BY 4.0).